Biblio

Nair P, Yamamoto T, Largent-Milnes TM, Cowell S, Kulkarni V, Moye S, Navratilova E, Davis P, Ma S-W, Vanderah TW et al..  2013.  Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.. Bioorg Med Chem Lett. 23(17):4975-8.

Singh M, Simpkins JW, Simpkins JW, Bimonte-Nelson HA, Bimonte-Nelson HA, Brinton RDiaz.  2013.  Window of opportunity for estrogen and progestin intervention in brain aging and Alzheimer's disease.. Brain Res. 1514:1-2.

Roesly HB, Khan MR, Chen HDau Rw, Hill KA, Narendran N, Watts GS, Chen X, Dvorak K.  2012.  The decreased expression of Beclin-1 correlates with progression to esophageal adenocarcinoma: the role of deoxycholic acid.. Am J Physiol Gastrointest Liver Physiol. 302(8):G864-72.

Béguin C, Potuzak J, Xu W, Liu-Chen L-Y, Streicher JM, Groer CE, Bohn LM, Carlezon WA, Cohen BM.  2012.  Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.. Bioorg Med Chem Lett. 22(2):1023-6.

Yao J, Brinton RDiaz.  2012.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.. Adv Pharmacol. 64:327-71.

Lochhead JJ, Thorne RG.  2012.  Intranasal delivery of biologics to the central nervous system.. Adv Drug Deliv Rev. 64(7):614-28.

Jandova J, Beyer TE, Meuillet EJ, Watts GS.  2012.  The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration.. Cell Biochem Funct. 30(8):687-95.

Brinton RDiaz.  2012.  Minireview: translational animal models of human menopause: challenges and emerging opportunities.. Endocrinology. 153(8):3571-8.

Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.

Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.

Zhao L, Mao Z, Schneider LS, Brinton RD.  2011.  Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause.. Menopause. 18(10):1131-42.

North American Menopause Society.  2011.  The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).. Menopause. 18(7):732-53.

Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RDiaz.  2011.  Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.. Mol Aspects Med. 32(4-6):247-57.

Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, Varga E, Vanderah T, Porreca F, Lai J et al..  2011.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.

Yao J, Brinton RDiaz.  2011.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.. Curr Pharm Des. 17(31):3474-9.

Henderson VW, Brinton RDiaz.  2010.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.. Prog Brain Res. 182:77-96.

Largent-Milnes TM, Vanderah TW.  2010.  Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.

Brinton RDiaz.  2009.  Estrogen-induced plasticity from cells to circuits: predictions for cognitive function.. Trends Pharmacol Sci. 30(4):212-22.

Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS et al..  2009.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.. Am J Gastroenterol. 104(2):302-9.

Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RDiaz.  2009.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 106(34):14670-5.

Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW.  2008.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.. Neoplasia. 10(5):450-61.

Wang JMing, Liu L, Brinton RDiaz.  2008.  Estradiol-17beta-induced human neural progenitor cell proliferation is mediated by an estrogen receptor beta-phosphorylated extracellularly regulated kinase pathway.. Endocrinology. 149(1):208-18.

Brinton RDiaz.  2008.  Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease.. Adv Drug Deliv Rev. 60(13-14):1504-11.

Brinton RDiaz.  2008.  The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications.. Trends Neurosci. 31(10):529-37.

Brinton RDiaz, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, Morgan TE, Pike CJ, Mack WJ, Stanczyk FZ et al..  2008.  Progesterone receptors: form and function in brain.. Front Neuroendocrinol. 29(2):313-39.